Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Tocilizumab for Relapsed Hematological Malignancies Post-Transplant
NCT03588936Phase 1Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in hematological malignancy (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Maximum-tolerated Dose at 3 months. Started Sep 2018; status: terminated.
02
Drugs
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT03588936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588936.